Thursday, July 9, 2026

pharma · HER2-positive · CARM

Carisma Therapeutics

Carisma Therapeutics is a pharma organization headquartered in Philadelphia, USA. It trades on NYSE under ticker CARM. Primary therapeutic focus areas include HER2-positive. NovaPharmaNews links 2 clinical program(s), 0

Philadelphia, USA HQ
2016 Founded
15 Employees
Public company Type
CARM · NYSE Ticker
Company details
Status
Public
HQ
Philadelphia, USA
Founded
2016
Employees
15
Programs
2
Drugs
1
Patents
2
Clinical program

CT-0525

Phase 1 · small molecule · HER2-positive

CT-0525 for HER2-positive is a Phase 1 program (small_molecule) at Carisma Therapeutics with 1 ClinicalTrials.gov record(s).

← All Carisma Therapeutics projects Phase 1 small molecule active

Internal code Study 102

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Carisma Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
HER2-positive
Status
active
Trials
1

Clinical trials